Activating the NLRP3 Inflammasome Using the Amyloidogenic Peptide IAPP
In addition to several other extracellular substances, phagocytosis of amyloid-forming peptides can perturb cellular homeostasis, leading to activation of the cytoplasmic innate immune receptor NLRP3. Once triggered, NLRP3 forms an inflammasome complex that ultimately cleaves pro-IL-1β and pro-IL-18 into their mature, secreted forms. Here we describe a protocol by which one type of amyloidogenic peptide, islet amyloid polypeptide (IAPP, otherwise known as amylin) can be prepared and used to stimulate myeloid cells in vitro to engage the NLRP3 inflammasome. Methods for measuring the ensuing inflammasome activation are also described. Although initially soluble, IAPP monomers rapidly aggregate in solution to form oligomers and subsequently insoluble amyloid fibrils. More work is required to examine how this transition influences inflammasome activation for different types of amyloid. The course of amyloid formation and corresponding inflammatory capacity of these pre-fibrillar species following uptake also requires further examination, and we hope that our protocols are useful in these endeavors. While these protocols are restricted to examination of synthetic IAPP, isolation of IAPP aggregates from human and transgenic mouse pancreas will be required to definitively determine the proinflammatory effects of endogenous IAPP oligomers and fibrils.
Key wordsInflammasome Amyloid Innate immunology NLR IAPP
The authors would like to thank Ben A. Croker for initially optimizing the IL-18 ELISA protocol. S.L.M. is supported by a fellowship from the National Health and Medical Research Council of Australia (516783). C.W.R. is supported by a Vanier Canada Graduate Scholarship and C.B.V. by grants from the Canadian Institutes of Health Research (MOP-14862) and 20R66631 and the Canadian Diabetes Association (OG-3-11-3413-CV).
- 2.Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155–161. doi:10.1038/ni.1836, doi:ni.1836 [pii] PubMedCrossRefGoogle Scholar
- 3.Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC, Poynter ME (2011) Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol 187(1):64–73. doi:10.4049/jimmunol.1100500, doi:jimmunol.1100500 [pii] PubMedCrossRefGoogle Scholar
- 5.Niemi K, Teirila L, Lappalainen J, Rajamaki K, Baumann MH, Oorni K, Wolff H, Kovanen PT, Matikainen S, Eklund KK (2011) Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol 186(11):6119–6128. doi:10.4049/jimmunol.1002843, doi:jimmunol.1002843 [pii] PubMedCrossRefGoogle Scholar
- 6.Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nunez G, Yodoi J, Kahn SE, Lavelle EC, O’Neill LA (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11(10):897–904. doi:10.1038/ni.1935, doi:ni.1935 [pii] PubMedCrossRefGoogle Scholar